Trial · NCT03573596
Persistence of MR3 in Chronic Myeloid Leukemia (CML) After a 2nd Stop of TKI Treatment
NCT03573596, Phase 2, Unknown, Amsterdam UMC, location VUmc
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Persistence of MR3 in Chronic Myeloid Leukemia (CML) After a 2nd Stop of TKI Treatment. Trials, record NCT03573596. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03573596
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Persistence of MR3 in Chronic Myeloid Leukemia (CML) After a 2nd Stop of TKI Treatment
- NCT number
- NCT03573596
- Status
- Unknown
- Phases
- Phase 2
- Enrollment
- 134 participants, estimated
- Lead sponsor
- Amsterdam UMC, location VUmc
- Conditions
- CML, Relapsed
- Interventions
- Dasatinib
- First posted
- 2018-06-29
- Last updated
- 2018-06-29
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | successful MMR maintenance | one year | The proportion of patients maintaining MMR at 12 months after discontinuing TKI a second time (survival without loss of major molecular response, MMR, defined as BCR-ABL1 \> 0.1% on IS at one time point). |
| Secondary | correlates with succesful stop | 1 year | Assessment of clinical and biological factors correlating with persistence of MMR or better after second TKI stop. |
| Secondary | reachievement of MR4 | 1 year | Number of patients who re-achieved stable MR4, and were offered study participation. |
| Secondary | Time to reachievement of MR4 | 1 year | Time to reachievement of MR4 after second loss of MMR. |
| Secondary | Adverse events after TKI withdrawal | 1 year | Adverse events related to second TKI stop, clinical and biological factors correlated to development of these AEs. |
| Secondary | Overall survival | 1 year | Overall survival |
| Secondary | Progression-free survival | 1 year | Progression-free survival |
| Secondary | TKI restart without prior molecular relapse | 1 year | Occurrence of a restart of TKI without prior molecular relapse. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 38278960 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03573596
GET https://conductscience.org/api/trials/v1/NCT03573596/registered